Fu-Yue Zeng's Research Focus
Dr. Zeng is Associate Director of High Throughput Screening and Compound Management at SBP’s Prebys Center. The center is equipped with state of the art ultra High Throughput Drug Screening (HTS) and lead discovery capabilities. His overall goal is to assist the center to execute high throughput screening projects, and to provide compound support for the Prebys Center team and principle investigators at the institute to enable the overall mission of the institute to translate basic research into therapies for patients.
Fu-Yue Zeng's Bio
Dr. Zeng has over 20 years of drug discovery and development experience, including 8 years with biotech companies. Before joining industry, Dr. Zeng was a staff scientist at National Institute of Health where he studied the structure and function of G-protein coupled receptors (GPCR). His work included the identification of key motifs, which activate muscarinic receptors, as well as the first discovery and characterization of muscarinic receptor dimerization.
In 1999, he took a team leader position at Arena Pharmaceuticals Inc. in San Diego, California, where he worked on developing novel GPCR screening assay platforms and drug discovery projects. In 2004, he transitioned to principal scientist at Novasite Pharmaceuticals Inc. in San Diego, where he continued on different GPCR drug discovery projects.
Dr. Zeng joined St. Jude Children Research Hospital at Memphis, Tennessee in 2007 where he helped establish a world-class automation high throughput screening system and managed a screening and drug discovery team. The team pursued projects in all classes of targets. He went on to join SBP in 2009, where he is Associate Director of High Throughput Screening and Compound Management.
Dr. Zeng received his Ph.D. from the Faculty of Pharmacy of the Philips University of Marburg, Germany.
- Staff Scientist (1997 – 1999) NIDDK, NIH, Bethesda, Maryland
- Team Leader (1999 - 2004) Arena Pharmaceuticals Inc, San Diego, California.
- Principal Scientist (2004 – 2007) Novasite Pharmaceuticals Inc, San Diego, California
- Principal Scientist (2007-2009) Chemical Biology Department, St. Jude Children Research Hospital, Memphis, Tennessee
Fatty acylation of the rat asialoglycoprotein receptor. The three subunits from active receptors contain covalently bound palmitate and stearate.
Zeng FY, Kaphalia BS, Ansari GA, Weigel PH
J Biol Chem 1995 Sep 8 ;270(36):21382-7
Use of a disulfide cross-linking strategy to study muscarinic receptor structure and mechanisms of activation.
Zeng FY, Hopp A, Soldner A, Wess J
J Biol Chem 1999 Jun 4 ;274(23):16629-40
Ligand specific up-regulation of a Renilla reniformis luciferase-tagged, structurally unstable muscarinic M3 chimeric G protein-coupled receptor.
Zeng FY, McLean AJ, Milligan G, Lerner M, Chalmers DT, Behan DP
Mol Pharmacol 2003 Dec ;64(6):1474-84
Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells.
Feng Y, Sessions EH, Zhang F, Ban F, Placencio-Hickok V, Ma CT, Zeng FY, Pass I, Terry DB, Cadwell G, Bankston LA, Liddington RC, Chung TDY, Pinkerton AB, Sergienko E, Gleave M, Bhowmick NA, Jackson MR, Cherkasov A, Ronai ZA
Cancer Lett 2019 May 1 ;449:145-162
Cell-Based High-Throughput Luciferase Reporter Gene Assays for Identifying and Profiling Chemical Modulators of Endoplasmic Reticulum Signaling Protein, IRE1.
Rong J, Pass I, Diaz PW, Ngo TA, Sauer M, Magnuson G, Zeng FY, Hassig CA, Jackson MR, Cosford ND, Matsuzawa S, Reed JC
J Biomol Screen 2015 Dec ;20(10):1232-45
Ultra-High-Throughput Screening of Natural Product Extracts to Identify Proapoptotic Inhibitors of Bcl-2 Family Proteins.
Hassig CA, Zeng FY, Kung P, Kiankarimi M, Kim S, Diaz PW, Zhai D, Welsh K, Morshedian S, Su Y, O'Keefe B, Newman DJ, Rusman Y, Kaur H, Salomon CE, Brown SG, Baire B, Michel AR, Hoye TR, Francis S, Georg GI, Walters MA, Divlianska DB, Roth GP, Wright AE, Reed JC
J Biomol Screen 2014 Sep ;19(8):1201-11
Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor.
Maloney PR, Khan P, Hedrick M, Gosalia P, Milewski M, Li L, Roth GP, Sergienko E, Suyama E, Sugarman E, Nguyen K, Mehta A, Vasile S, Su Y, Stonich D, Nguyen H, Zeng FY, Novo AM, Vicchiarelli M, Diwan J, Chung TD, Smith LH, Pinkerton AB
Bioorg Med Chem Lett 2012 Nov 1 ;22(21):6656-60